Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

81. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials (PubMed)

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials Aside from lowering blood glucose, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) attract much attention because of their cardioprotective effects. The aim of this study was to assess the blood pressure-lowering effects of the GLP-1 RAs exenatide and liraglutide compared with other common drugs used to treat type 2 diabetes (T2DM) based on randomized controlled trials (...) (RCTs) including data describing complete blood pressure (BP) changes from baseline.We searched the major databases for published or unpublished RCTs that had been performed in patients with T2DM and compared the effects of exenatide and liraglutide to those of other common drugs used to treat T2DM. The RCTs that included data describing BP changes between the baseline and the end of the study were selected for further analysis.A total of 16 RCTs that enrolled 3443 patients in the GLP-1 RA treatment

2013 EvidenceUpdates

82. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo (PubMed)

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exenatide once weekly (ExQW) and liraglutide once daily (QD) are indicated to improve glycaemic control in patients with type 2 diabetes. Although glycaemic control with ExQW versus liraglutide QD 1.8 mg has been directly (...) compared, no studies have compared ExQW with liraglutide QD 1.2 mg or determined the probable relative efficacies of various injectable therapies for glycaemic control; therefore, a network meta-analysis was performed to address these questions.A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo. Twenty-two studies evaluating 11 049 patients were included in the network

2013 EvidenceUpdates

83. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. (PubMed)

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes. We compared the efficacy and safety of exenatide once weekly with liraglutide once daily in patients with type 2 diabetes.We did a 26 week, open-label, randomised, parallel-group study at 105 sites (...) in 19 countries between Jan 11, 2010, and Jan 17, 2011. Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg). Participants and investigators were not masked to treatment assignment. The primary endpoint was change in glycated haemoglobin

2013 Lancet

84. Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets (Full text)

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%.In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run (...) -in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks' open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change between randomized groups.Of 821 participants completing the run-in, 61% (n = 498) achieved A1C <7% (mean change -1.3% from 7.7% at start), whereas 39% (n = 323) did not (-0.6% from 8.3% at start

2012 EvidenceUpdates PubMed

85. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

86. Liraglutide (Victoza) in type 2 diabetes. Similar to exenatide

Liraglutide (Victoza) in type 2 diabetes. Similar to exenatide 2011. DAR No 11. Liraglutide (Victoza®) in type 2 diabetes - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 11. Liraglutide (Victoza®) in type 2 diabetes DAR No 11. Liraglutide (Victoza®) in type 2 diabetes Content tools Share it Similar to exenatide The efficacy of liraglutide is similar to glimepiride and slightly higher than glargine and exenatide, although the clinical

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

87. Liraglutide - Diabetes, Type 2

Liraglutide - Diabetes, Type 2 Common Drug Review CEDAC Meeting – June 15, 2011; CEDAC Reconsideration – September 21, 2011 Notice of CEDAC Final Recommendation – September 28, 2011 Page 1 of 7 © 2011 CADTH CEDAC FINAL RECOMMENDATION LIRAGLUTIDE (Victoza – Novo Nordisk Canada Inc.) Indication: Diabetes, Type 2 Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that liraglutide not be listed at the submitted price. Reasons for the Recommendation: 1. Based (...) on a systematic review including six randomized controlled trials (RCTs), liraglutide demonstrated similar or greater reductions in hemoglobin A1c in combination with metformin, or with metformin and a sulfonylurea, compared with antihyperglycemic agents from other drug classes. Liraglutide was also associated with statistically significant weight loss compared with other drug classes. The clinical significance of these results with respect to diabetes-related morbidity and mortality is unknown for this new

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

88. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

89. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

90. Victoza (Liraglutide [rDNA]) Injection

Victoza (Liraglutide [rDNA]) Injection Drug Approval Package: Victoza (Liraglutide [rDNA]) Injection Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Victoza (Liraglutide [rDNA]) Injection Company: Novo Nordisk Inc. Application No.: 022341 Approval Date: 1/25/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

91. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. (PubMed)

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Agonists of the glucagon-like peptide-1 (GLP-1) receptor provide pharmacological levels of GLP-1 activity, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors increase concentrations of endogenous GLP-1 and glucose-dependent insulinotropic polypeptide. We aimed to assess the efficacy and safety of the human GLP-1 (...) analogue liraglutide versus the DPP-4 inhibitor sitagliptin, as adjunct treatments to metformin, in individuals with type 2 diabetes who did not achieve adequate glycaemic control with metformin alone.In this parallel-group, open-label trial, participants (aged 18-80 years) with type 2 diabetes mellitus who had inadequate glycaemic control (glycosylated haemoglobin [HbA(1c)] 7.5-10.0%) on metformin (>or=1500 mg daily for >or=3 months) were enrolled and treated at office-based sites in Europe, the USA

2010 Lancet

92. Victoza (liraglutide (genetical recombination))

Victoza (liraglutide (genetical recombination)) ???? ??? 2.6.2.5 ?? ??? ??? ???? Page1 This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA shall not be responsible for any consequence resulting from the use of this English version. Report on the Deliberation Results December 3, 2009 Evaluation (...) and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Victoza Subcutaneous Injection 18 mg [Non-proprietary name] Liraglutide (Genetical Recombination) (JAN*) [Applicant] Novo Nordisk Pharma Ltd. [Date of application] July 14, 2008 [Results of deliberation] In the meeting held on November 27, 2009, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs

2010 Pharmaceuticals and Medical Devices Agency, Japan

93. Liraglutide for the treatment of type 2 diabetes mellitus

Liraglutide for the treatment of type 2 diabetes mellitus Liraglutide for the treatment of type 2 diabetes mellitus Liraglutide for the treatment of type 2 diabetes mellitus National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Liraglutide for the treatment (...) of type 2 diabetes mellitus. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 203. 2010 Authors' conclusions 1.1 Liraglutide 1.2 mg daily in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in ‘Type 2 diabetes: the management of type 2 diabetes’ (NICE clinical guideline

2010 Health Technology Assessment (HTA) Database.

94. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

Liraglutide for the treatment of type 2 diabetes mellitus (TA203) Liraglutide for the treatment of type 2 diabetes mellitus | Guidance | NICE Liraglutide for the treatment of type 2 diabetes mellitus Technology appraisal guidance [TA203] Published date: 27 October 2010 Last updated: 01 December 2014 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

95. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). (Full text)

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.In total, 1041 adults (mean (...) %) when added to glimepiride. Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2

2009 EvidenceUpdates PubMed

96. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. (PubMed)

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder.In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 (...) diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks. The primary outcome was change in proportion of glycosylated haemoglobin (HbA(1c)). Analysis was done by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NTC00294723.At 52 weeks, HbA(1c) decreased by 0.51% (SD 1.20%) with glimepiride, compared with 0.84% (1.23%) with liraglutide 1.2 mg (difference -0.33%; 95% CI -0.53 to -0.13, p=0.0014

2009 Lancet

97. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). (PubMed)

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. We compared the efficacy and safety of liraglutide, a human GLP-1 analogue, with exenatide, an exendin-based GLP-1 receptor agonist.Adults with inadequately controlled type 2 diabetes on maximally (...) tolerated doses of metformin, sulphonylurea, or both, were stratified by previous oral antidiabetic therapy and randomly assigned to receive additional liraglutide 1.8 mg once a day (n=233) or exenatide 10 microg twice a day (n=231) in a 26-week open-label, parallel-group, multinational (15 countries) study. The primary outcome was change in glycosylated haemoglobin (HbA(1c)). Efficacy analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00518882.Mean baseline

2009 Lancet

98. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. (PubMed)

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The frequency of obesity has risen dramatically in recent years but only few safe and effective drugs are currently available. We assessed the effect of liraglutide on bodyweight and tolerability in obese individuals without type 2 diabetes.We did a double-blind, placebo-controlled 20-week trial, with open-label orlistat comparator in 19 sites in Europe. 564 individuals (18-65 years of age (...) , body-mass index 30-40 kg/m2) were randomly assigned, with a telephone or web-based system, to one of four liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg, n=90-95) or to placebo (n=98) administered once a day subcutaneously, or orlistat (120 mg, n=95) three times a day orally. All individuals had a 500 kcal per day energy-deficit diet and increased their physical activity throughout the trial, including the 2-week run-in. Weight change analysed by intention to treat was the primary endpoint

2009 Lancet

99. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus

A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the long-term clinical and economic impact of liraglutide versus glimepiride as monotherapies in patients with type 2 diabetes mellitus. The authors concluded that liraglutide

2009 NHS Economic Evaluation Database.

100. Liraglutide (NN-2211) for type 2 diabetes: horizon scanning technology briefing

Liraglutide (NN-2211) for type 2 diabetes: horizon scanning technology briefing Liraglutide (NN-2211) for type 2 diabetes: horizon scanning technology briefing Liraglutide (NN-2211) for type 2 diabetes: horizon scanning technology briefing National Horizon Scanning Centre Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Horizon (...) Scanning Centre. Liraglutide (NN-2211) for type 2 diabetes: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2007 Authors' objectives This study examines the use of Liraglutide (NN-2211) for type 2 diabetes. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2 /drug therapy Language Published English Country of organisation England Address for correspondence Department of Public Health and Epidemiology, The University

2007 Health Technology Assessment (HTA) Database.